Opexa Therapeutics, Inc. (ACER) Downgraded by ValuEngine
ValuEngine lowered shares of Opexa Therapeutics, Inc. (NASDAQ:ACER) from a hold rating to a sell rating in a report published on Monday.
Shares of Opexa Therapeutics (NASDAQ ACER) opened at 15.33 on Monday. The firm’s market cap is $11.33 million. Opexa Therapeutics has a one year low of $5.21 and a one year high of $45.62. The company has a 50 day moving average of $10.60 and a 200-day moving average of $8.34.
COPYRIGHT VIOLATION WARNING: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/05/opexa-therapeutics-inc-acer-downgraded-by-valuengine.html.
About Opexa Therapeutics
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related stocks with our FREE daily email newsletter.